Sabbin Bayanai Na Asibiti Mai Kyau a cikin Marasa lafiya masu Ciwon Ciki

Za a gabatar da sakamakon binciken (Abstract # 519) yau da ƙarfe 10:00 na safe ET yayin wani taro mai sauri a taron 2022 American Society for Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.      

Dokta Tanios S. Bekaii-Saab, wani mai bincike na binciken KRYSTAL-1, ya yi sharhi, "Cutar daji na hanji wasu daga cikin cututtukan daji da aka fi sani da su kuma suna ci gaba da kasancewa tare da mummunan sakamakon rayuwa duk da ci gaban da aka samu a baya-bayan nan, musamman ma marasa lafiya da ciwon GI. maye gurbin KRASG12C. Sabbin bayanan asibiti da aka gabatar a ASCO GI sun nuna cewa adagrasib, mai hanawa na KRASG12C, ya nuna alamun aikin asibiti a cikin marasa lafiya da ciwon daji na pancreatic da sauran ciwan GI. Wadannan binciken sun gina kan ingantaccen bayanan asibiti na adagrasib da aka bayar a baya a cikin ciwon daji na launin fata da na pancreatic, kuma suna da kwarin gwiwa sosai, suna ba da garantin ƙarin bincike na adagrasib a cikin wannan yanayin."

Takaitacciyar Sakamako na Clinical

• Tun daga ranar 10 ga Satumba, 2021, rukunin marasa lafiya masu fama da cutar kansar GI da ke ɗauke da maye gurbin KRASG12C da aka yi rajista a hannun adagrasib monotherapy (n=30) sun karɓi aƙalla layukan da suka gabata na tsarin maganin cutar kansa, kuma suna da matsakaicin bin watanni 6.3. .

• Daga cikin majinyatan da ake kimantawa (n=27), ƙimar amsawar haƙiƙa (ORR) shine 41% kuma ƙimar kula da cututtuka (DCR) shine 100%. A cikin marasa lafiya masu ƙima tare da ciwon daji na pancreatic (n = 10), ƙimar amsawa (RR) shine 50%, ciki har da 1 amsa juzu'i (PR); Matsakaicin lokacin amsawa (mDOR) shine watanni 7.0, tare da matsakaicin bin watanni 8.1. A cikin marasa lafiya tare da wasu ciwace-ciwacen GI (n = 17), RR shine 35%, tare da PRs guda biyu da ba a tabbatar da su ba; mDOR ya kasance watanni 7.9 a cikin waɗannan marasa lafiya, tare da matsakaicin bin watanni 6.3.

• Matsakaicin ci gaba na rayuwa kyauta (mPFS) a cikin marasa lafiya da ciwon daji na pancreatic shine watanni 6.6 (95% Interval Interval, CI: 1.0, 9.7), kuma a cikin marasa lafiya tare da sauran ciwan GI, mPFS shine watanni 7.9 (95% CI 6.90- 11.30).

• A cikin jimlar marasa lafiya tare da KRASG12C-mutated GI cancers da aka kimanta a cikin wannan rukunin, adagrasib ya kasance mai jurewa da kyau, tare da bayanin martabar aminci mai sarrafawa. An lura da abubuwan da ba su da kyau na 3/4 na jiyya (TRAEs) a cikin 27% na marasa lafiya da aka bi da su tare da adagrasib, ba tare da TRAEs da ke haifar da dakatar da jiyya ba, kuma ba a lura da TRAEs na Grade 5 ba.

"Mun yi imanin adagrasib yana da nau'i mai mahimmanci na kwayoyin halitta, kuma bayanan da aka gabatar a ASCO GI sun kara tallafawa yiwuwar mafi kyawun bayanin martaba," in ji Charles M. Baum, MD, Ph.D., wanda ya kafa, shugaban kasa da kuma shugaban bincike da bincike. ci gaba, Mirati Therapeutics, Inc. "Sakamakon ya nuna kyakkyawan aiki na asibiti a cikin marasa lafiya tare da KRASG12C-mutated GI cancers da aka bi da su tare da adagrasib wakili guda ɗaya, musamman a cikin wadanda ke da ciwon daji na pancreatic inda zaɓuɓɓukan sun iyakance. Muna ci gaba da kimanta adagrasib a matsayin wakili guda ɗaya kuma tare da sauran magungunan kansa a cikin babban shirin haɓaka don taimakawa ƙarin mutanen da ke fama da cutar kansa.